Anfield Energy Submits Plan of Operation to the State of Utah for the Velvet-Wood Mine as the Company Continues its March Towards Uranium Production

May 1, 2024

VANCOUVER, British Columbia, May 01, 2024 – Anfield Energy, Inc. (TSX.V: AEC; OTCQB: ANLDF; FRANKFURT: 0AD) (“Anfield” or “the Company”) is pleased to announce that it has submitted its Plan of Operation for its Velvet-Wood mine to the State of Utah and BLM....

Boba Mint Holdings Ltd. Approved for CSE Listing on April 26, 2024

Apr 26, 2024

Vancouver, British Columbia – April 25, 2024 – Boba Mint Holdings Ltd. (CSE: TNJ) (“Boba” or the “Company”) is pleased to announce that it has received final confirmation from the Canadian Securities Exchange (the “CSE”)...

Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID

Apr 23, 2024

TORONTO, April 23, 2024 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical...

Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product

Apr 18, 2024

TORONTO, April 18, 2024 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical...

PharmaDrug’s SecureDose Announces the Advancement of Process Development of Its Biosynthetic Formulation of Pharmaceutical Grade Cocaine

Apr 16, 2024

Victoria’s Chiral Labs to lead development of novel cocaine manufacturing process   Toronto, Ontario – April 16, 2024 – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company”), a specialty...

Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder

Apr 2, 2024

TORONTO, April 02, 2024 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased...